Monte Rosa Therapeutics, Inc.
GLUEFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Monte Rosa Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Dogwood Wealth Management LLC | 2026-03-31 | 54 | $888 | SEC filing |
| Alphabet Inc. | 2026-03-31 | 684,275 | $11.3M | SEC filing |
| State of Wyoming | 2026-03-31 | 17,645 | $290K | SEC filing |
| Aisling Capital Management LP | 2026-03-31 | 1,555,664 | $25.6M | SEC filing |
| MassMutual Private Wealth & Trust, FSB | 2026-03-31 | 103 | $1.69K | SEC filing |
| FMR LLC | 2026-03-31 | 1,024,304 | $16.8M | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 24,319 | $400K | SEC filing |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2026-03-31 | 4,226,809 | $69.5M | SEC filing |
| OSAIC HOLDINGS, INC. | 2026-03-31 | 1,594 | $26.2K | SEC filing |
| WEALTH EFFECTS LLC | 2026-03-31 | 10,099 | $166K | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 7,388 | $122K | SEC filing |
| E Fund Management Co., Ltd. | 2026-03-31 | 13,151 | $216K | SEC filing |
| LPL Financial LLC | 2026-03-31 | 14,450 | $238K | SEC filing |
| Sunbelt Securities, Inc. | 2026-03-31 | 1 | $16 | SEC filing |
| OpenArc Corporate Advisory, LLC | 2026-03-31 | 100,227 | $1.65M | SEC filing |
| Man Group plc | 2026-03-31 | 25,262 | $416K | SEC filing |
| Mayflower Financial Advisors, LLC | 2026-03-31 | 10,000 | $165K | SEC filing |
| MAI Capital Management | 2026-03-31 | 227 | $3.74K | SEC filing |
| MERCER GLOBAL ADVISORS INC /ADV | 2026-03-31 | 12,106 | $199K | SEC filing |
| KLP KAPITALFORVALTNING AS | 2026-03-31 | 6,800 | $112K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Monte Rosa Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-24 · Janku Filip: Larger than 36 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-10-29 · Versant Venture Capital VI, L.P.: Larger than 37 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-10-28 · Versant Venture Capital VI, L.P.: Larger than 38 of the 40 other insider sales of Common Stock on file. SEC filing
- 2024-09-20 · Versant Venture Capital VI, L.P.: Larger than all 40 other insider sales of Common Stock on file. SEC filing
- 2024-09-11 · Versant Venture Capital VI, L.P.: Larger than 39 of the 40 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2021-06-28–2021-06-28: 11 event(s) across 11 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-29 | Janku Filip · Chief Medical Officer | Common Stock | S — Open market or private sale | −6,000 | 22.95 | SEC filing |
| 2026-06-29 | Manning Anthony M. · Director | Common Stock | S — Open market or private sale | −10,000 | 23.11 | SEC filing |
| 2026-06-24 | Janku Filip · Chief Medical Officer | Common Stock | S — Open market or private sale | −30,000 | 21.42 | SEC filing |
| 2026-06-23 | Townson Sharon · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,000 | 20.00 | SEC filing |
| 2026-06-23 | Janku Filip · Chief Medical Officer | Common Stock | S — Open market or private sale | −11,845 | 20.22 | SEC filing |
| 2026-06-23 | Champoux Jennifer · Chief Operating Officer | Common Stock | S — Open market or private sale | −2,175 | 20.00 | SEC filing |
| 2026-06-17 | Townson Sharon · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,000 | 19.00 | SEC filing |
| 2026-06-17 | Champoux Jennifer · Chief Operating Officer | Common Stock | S — Open market or private sale | −2,176 | 19.00 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-29 | Janku Filip · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +6,000 | SEC filing |
| 2026-06-29 | Manning Anthony M. · Director | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −10,000 | SEC filing |
| 2026-06-29 | Manning Anthony M. · Director | Common Stock | M — Exercise or conversion of derivative security | +10,000 | SEC filing |
| 2026-06-29 | Janku Filip · Chief Medical Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −6,000 | SEC filing |
| 2026-06-24 | Janku Filip · Chief Medical Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −30,000 | SEC filing |
| 2026-06-24 | Janku Filip · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +30,000 | SEC filing |
| 2026-06-23 | Champoux Jennifer · Chief Operating Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −2,175 | SEC filing |
| 2026-06-23 | Janku Filip · Chief Medical Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −6,000 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | +5,499 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −1,019,867 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −366,590 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | +20,397 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −20,397 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −5,499 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −5,454 | SEC filing |
| 2024-10-28 | Versant Venture Capital VI, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −17,595 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.